Risk factor
Considerable default risk
Profitability factor
Good growth
About
GPI S.p.A. delivers specialized IT and high-tech services to the healthcare and social-healthcare markets. The company develops a wide range of software solutions covering critical areas such as health administration, clinical systems, social care, blood and tissue banking, human resource management, continuum care, public administration, safety and prevention, chronic illness management, patient care, business intelligence, data analytics, health cooperation, and people relationship management. Beyond software, GPI delivers key healthcare administration services, including advanced centralized booking and contract systems designed to significantly reduce patient waiting times, alongside innovative healthcare technologies and broader healthcare support. Their product portfolio features the Phasys System, an integrated hardware and software platform for optimizing medication management in healthcare facilities, and the RIEDL Phasys System, which automates medicine distribution within pharmacies. Furthermore, GPI offers general ICT services, payment solutions for both public administration and retail, and a comprehensive suite of desktop services. These desktop services encompass the design, implementation, and ongoing maintenance of technological infrastructures; IT consultancy and support; provision of solutions for public administrations; and help desk and facility management for a diverse clientele including local and central public bodies, healthcare providers, multi-utilities, and private enterprises. They also specialize in trouble ticketing systems and the design of integrated technological solutions. Established in 1988 and headquartered in Trento, Italy, GPI S.p.A. operates as a subsidiary of FM S.r.l.
Company Valuation
From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks. Specifically, the stock is fairly valued on P/E, neutral on EV/EBIT
Target Price
The average target price of GPI.MI is 18.2 and suggests 22.9% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to in